Lyra Therapeutics, Inc. (LYRA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
LYRA currently has 1.77M outstanding shares. with significant dilution risk as 48.6M authorized shares could dilute existing holders by 2748.0%. The company has minimally diluted shareholders by 8.49% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 12, 2025 |
10-Q filing | 1.8M shares outstanding |
1.8M | 49M |
| Aug 12, 2025 |
10-Q filing | 1.6M shares outstanding |
1.6M | 49M |
| Jul 22, 2025 |
S-1 filing: The selling securityholders may offer and sell up to 846,744 shares of common stock issuable upon exercise of warrants. |
66M | 49M |
| May 06, 2025 |
10-Q filing | 65.8M shares outstanding |
66M | 48M |
| Mar 13, 2025 |
10-K filing | 65.1M shares outstanding |
65M | 48M |
| Nov 12, 2024 |
10-Q filing | 65.5M shares outstanding |
65M | 48M |
| Aug 14, 2024 |
10-Q filing | 65.5M shares outstanding |
65M | 48M |
| Apr 30, 2024 |
10-Q filing | 64.0M shares outstanding |
64M | 48M |
| Mar 22, 2024 |
10-K filing | 59.7M shares outstanding |
60M | 48M |
| Mar 22, 2024 |
S-3 filing: Lyra Therapeutics, Inc. files an S-3 to offer and sell up to $300,000,000 in the aggregate of common stock, preferred stock, and debt securities. |
57M | 48M |
| Nov 07, 2023 |
10-Q filing | 57.0M shares outstanding |
57M | 48M |
| Aug 08, 2023 |
10-Q filing | 49.5M shares outstanding |
50M | 48M |
| Jun 28, 2023 |
S-3 filing: Lyra Therapeutics, Inc. is filing an S-3 registration statement for the offering of up to 21,967,353 shares of common stock by selling securityholders. |
12M | 48M |
| May 12, 2023 |
10-Q filing | 31.8M shares outstanding |
32M | 26M |
| Mar 29, 2023 |
10-K filing | 30.2M shares outstanding |
30M | 26M |
| Nov 08, 2022 |
10-Q filing | 31.8M shares outstanding |
32M | 26M |
| Aug 09, 2022 |
10-Q filing | 31.8M shares outstanding |
32M | 26M |
| May 11, 2022 |
S-3 filing: Shelf offering of 15,521,322 shares of common stock by selling securityholders, including shares issuable upon exercise of warrants. |
11M | 26M |
| May 10, 2022 |
10-Q filing | 31.8M shares outstanding |
32M | 10M |
| Mar 09, 2022 |
10-K filing | 13.0M shares outstanding |
13M | 10M |
| Nov 09, 2021 |
10-Q filing | 13.0M shares outstanding |
13M | 10M |
| Aug 09, 2021 |
10-Q filing | 13.0M shares outstanding |
13M | 10M |
| May 11, 2021 |
10-Q filing | 13.0M shares outstanding |
13M | 10M |
| May 11, 2021 |
S-3 filing: Lyra Therapeutics files an S-3 form to offer and sell up to $250,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings. |
13M | 10M |
| Mar 09, 2021 |
10-K filing | 12.9M shares outstanding |
13M | 4M |
| Nov 10, 2020 |
10-Q filing | 12.9M shares outstanding |
13M | 4M |
| Aug 05, 2020 |
10-Q filing | 12.9M shares outstanding |
13M | 4M |
| May 28, 2020 |
10-Q filing | 12.9M shares outstanding |
13M | 4M |
| Apr 27, 2020 |
S-1/A filing: Lyra Therapeutics, Inc. is offering 3,500,000 shares of its common stock in an initial public offering, with an expected public offering price between $14.00 and $16.00 per share. |
N/A | 4M |